Chandan Healthcare Limited — Investor Meet, 18-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Chandan Healthcare's Q3 FY26 earnings call highlighted robust performance with sales up 20% to INR65.77 Cr and EBITDA up 39% to INR12.61 Cr. PAT rose to INR4.54 Cr despite a one-time INR2.2 Cr gratuity provision. Management outlined significant expansion plans including 1000 franchisees in three years and new labs/centers across 13 states. A major INR55 Cr/year government radiology project in Punjab and Guwahati is expected to fuel "much higher" growth. The company aims for 30-35% sustainable EBITDA margins, driven by B2C and corporate business. Future focus includes molecular diagnostics and Tier 2/3/4 cities. The management's outlook is highly confident, projecting substantial future growth.